| Literature DB >> 15755607 |
Vidadi Yusibov1, Vadim Mett, Valentina Mett, Carley Davidson, Konstantin Musiychuk, Suzan Gilliam, Ann Farese, Thomas Macvittie, Dean Mann.
Abstract
We engineered a 21-mer peptide representing amino acids 170-190 of the respiratory syncytial virus (RSV) G protein as a fusion with the Alfalfa mosaic virus (AlMV) coat protein (CP), produced recombinant AlMV particles presenting this peptide (VMR-RSV) on their surfaces and tested the immunogenicity in vitro in human dendritic cells and in vivo in non-human primates. Significant pathogen-specific immune responses were generated in both systems: (i) human dendritic cells armed with VMR-RSV generated vigorous CD4+ and CD8+ T cell responses; (ii) non-human primates that received these particles responded by mounting strong cellular and humoral immune responses. This approach may validate the use of a novel RSV vaccine delivery vehicle in humans.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15755607 DOI： 10.1016/j.vaccine.2005.01.039
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641